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21. Abstract
Borna Disease is a severe, immunopathological disorder of the central nervous system
(CNS), caused by infection with Borna Disease virus (BDV). The main known
naturally affected animal species are horses and sheep in endemic areas in central
Europe. The detection of BDV in these hosts is achieved by histological,
immunohistochemical and serological approaches and/or PCR-based technologies.
In this study, we present the successful establishment of TaqMan® Real Time
RT-PCR for the detection of the transcripts of the two major proteins, p40
(nucleoproteinprotein) and p24 (phosphoprotein). The primers detect BDV with high
specificity and the approach also proved to be highly sensitive to detect both,
plasmids containing the p40 ORF and BDV from infected MDCK cells. In addition,
Real Time RT-PCR allowed the relative quantification of virus load from different
sheep and horse brain sites. These data were in complete agreement with previous
immunohistochemical studies using the same samples and therefore demonstrated that
the TaqMan® PCR approach is a valuable diagnostic and epidemiologic tool, which
allows for comparative studies using infected samples from various sources, e.g.,
different tissues, body fluids and excretions (i.e., liquor, serum, urine). In addition, we
tested the hypothesis whether the tick species Ixodes ricinus is a potential vector for
the transmission of BDV. Our results show, that BDV infected cells could be detected
over a period of one trough 24 days post feeding. However, in the course of time the
virus load per tick decreased close to background. Our observations do not necessarily
argue for or against ticks being vectors for BDV, but the experiments indicate that the
newly established Real Time RT-PCR may provide a useful tool for detecting such
vectors in endemic areas.
32. Introduction
Borna Disease (BD), a severe, immunopathological disorder of the central nervous
system (CNS), is caused by infection with Borna Disease virus (BDV) and the main
naturally affected animal species are horses and sheep in well circumscribed endemic
areas in central Europe.
2.1. History
Attention attracted by a disease of horses now known to be associated with BDV,
dates back several hundred years. The oldest reports describing typical characteristics
of BD are found in 1660, speaking of pain which pushes the horses or makes them
dull and dumb 1. In 1716, a book was published recording sleepiness, melancholia and
agitation in the course of such head pain 2. More precise reports of a disease affecting
the central nervous system in horses, called „disease of the head“, was found later in
the 18th and at the beginning of the 19th century 3,4. The disease became more
important in 1895 when almost all horses of a cavalry regiment in the town of Borna
in Saxony near Leipzig showed the typical symptoms of a severe disease of the
central nervous system 5. After this time point the name Borna Disease was adopted.
The famous investigations by Joest and Degen demonstrated that the disease was
paralleled by inflammatory reactions. Furthermore, they discovered the
pathognomonic appearance of intranuclear inclusion bodies, named Joest-Degen
bodies 6. The nature of the causing virus had remained obscure until the etiology of
BD had been established as early as 1925, when Zwick and Seifried proved it’s
transmissibility 7. More recently, BDV has been cultivated in different cell cultures 8,9,
including MDCK cells, and aspects of pathogenesis of the disease have been
elucidated 10,11. Furthermore the molecular characterisation of BDV 12-15 and its
replication strategy 16,17 have been achieved.
42.2. Etiology
2.2.1. Taxonomy and Morphology
BDV represents the only member of the new virus family Bornaviridae within the
order Mononegavirales. This order also includes Filoviridae (e.g., Marburg and Ebola
viruses), Paramyxoviridae (e.g., mumps, measles virus), and Rhabdoviridae (e.g.,
rabies, vesicular stomatitis virus) (see table 1). Electron microscopic studies of
negative-stained cell-free BDV infectious particles have shown that they are of
spherical morphology with a diameter ranging from 70 to 130nm 18-20. These particles
contain an internal electron-dense core (50 to 60nm) and a limiting outer membrane
envelope, which appears to be covered with spikes approximately 7.0nm long 20.
Virus infectivity is rapidly lost by treatment at 56°C, as well as at pH’s below 5 and
above 12, and by treatment with organic solvents, detergents, formaldehyde and
exposure to ultra violet radiation 21.
Order Mononegavirales
Family Bornaviridae Genus Bornavirus
Family Filoviridae Genus „Maburg-like viruses“
„Ebola-like viruses“
Family Paramyxoviridae
Subfamily Paramyxovirinae Genus Morbillivirus
Respirovirus
Rubulavirus
Subfamily Pneumovirinae Genus Pneumovirus
Metapneumovirus
Family Rhabdoviridae Genus Vesiculovirus
Lyssavirus
Ephemerovirus
Novirhabdovirus
Cytorhabdovirus
Nucleorhabdovirus
Table 1. Taxonomic structure of the order
There are four known virus strains: Borna V, Borna HE/80, Borna No/98, Borna
H1766. The genomes of these strains have been sequenced and published; strain
H1766 is almost 98% and 95% identical to strains V and HE/80, respectively, whereas
strain No/98 is about 81% identical to the reference strains. These findings show that
BDV is characterised by extraordinary sequence conservation uncommon for RNA
5viruses 14,15,22,23. Other BDV variants might be present outside the endemic regions and
Staeheli et al. (2000) also suggest that a great number of strains may exist worldwide
but the currently available detection methods only detect a fraction of them 24.
2.2.2. Genomic organisation
BDV is an enveloped, non-segmented, single- and negative-stranded RNA virus
(NNS RNA). Replication and transcription of the BDV genome occur in the cell
nucleus. While nuclear replication and transcription are found in segmented negative-
strand RNA viruses and nucleo-rhabdoviruses (NNS RNA viruses of plants), BDV is
the only known NNS RNA virus of animals with this property 25.
0     8,9kb
ORF I Nucleoprotein  (N) p38/40
ORF II Phosphoprotein (P) p24
ORF III Matrixprotein (M) p16
ORF IV Glycoprotein (G) p57
ORF V RNA Ploymerase (L) p190
ORF X (X) p10
Fig. 1. 6 Open Reading Frames (ORF)
The genome size is about 8.9 kilo bases, which makes it the smallest among known
negative-stranded RNA viruses. The organisation of the six major ORFs (see fig. 1) is
similar to that of other Mononegaviruses 26. Based on their positions in the viral
genome (3’-N-X-M-G-L-5’) and the features of the corresponding amino acid
sequences, these polypeptides are counterparts of the nucleoprotein (N),
phosphoprotein (P), matrix protein (M), surface glycoprotein (G) and polymerase (L),
respectively, which are also found in other negative-stranded RNA viruses 27.
Negative-stranded RNA viruses initiate infection by introducing their genetic material
in the form of ribonucleoprotein complexes into the host cells. These complexes,
which consist of the single-stranded RNA genome associated with the RNA-binding
protein N, the polymerase cofactor P and the RNA-dependent RNA polymerase L, are
transcriptionally active and direct the synthesis of viral mRNAs 28. After production of
sufficient amounts of newly synthesised viral proteins, replication is initiated and new
ORF I II
X
III
ORF IV
ORF V3‘ 5‘
6nucleocapsid can be formed. The major components of the nucleocapsid are N and P,
which are both present in various isoforms, as a result of alternative splicing and
internal translation initiation mechanisms. These mechanisms are also producing a
number of isoforms of the other nucleocapsid components. One reason for this variety
appears to be a mean for differential transcriptional activity. Specifically, it has been
shown that both the composition and stoichiometry of nucleocapsid components are
involved in the regulation of the BDV multiplication cycle 29-32. Based on these
distinct genetic features among known negative-stranded RNA viruses, BDV is
considered to be the prototypic member of a new virus family, Bornaviridae, within
the order Mononegavirales.
2.3. Hosts and Epidemiology
BDV infections mainly affect horses and sheep but the disease is not strictly limited to
these two hosts, although the incidence in other animals appears to be very low. BDV
was found in donkeys 33-37, goats 37 and cattle 38,39 with neurological disease and
prominent lymphocytic infiltrations of the CNS. Recently, BDV antigen and RNA
have been identified in the brain of two dogs with severe neurological disease that had
lived in Austria and Japan, respectively 40,41. Furthermore there is ongoing controversy
whether BDV induces “staggering disease” in cats 42-47. In a study from Switzerland,
one of 180 brains of cats with histologically confirmed CNS disease showed evidence
of BDV infection by immunohistochemistry  48. The other 179 cat brains were
negative for BDV by immunohistochemistry and RT-PCR 49. In addition, the presence
of BDV-specific RNA was demonstrated by in situ hybridisation in neurons of the
cerebral cortex of a cat with paralytic disease, but without CNS inflammation 50.
Altogether, these data strongly suggest, that although natural BDV infections of cats
may occur occasionally, BDV is not likely to be the aetiological agent of “staggering
disease”. However, the identification of BDV in hosts such as lynx 51, rabbits 52 and
even ostriches 53,54 indicates that the virus has a broad host repertoire of various birds
and mammals. Finally, experimental infection with BDV has been demonstrated in
many laboratory animals, such as rats, mice, rabbits and gerbils.
As already mentioned, Borna Disease received its name from an equine
outbreak in 1895/96 near the town Borna in Germany. More sporadic occurrence of
BD had since been described in different areas of Germany 55-57. The endemic area
7also includes parts of the upper Rhine valley between Switzerland, Austria and the
Principality of Liechtenstein 37,58. The Bündner  Herrschaft, Domleschg, Schanfigg
and the St. Galler Rheintal are the mainly affected areas in Switzerland. Although
BDV infections have been reported from northern Europe, USA, Japan, Iran and
Israel 59 60,61, clinical cases of horses and sheep have rarely been reported outside the
endemic area 62. On the other hand, sero-epizootiological studies have shown that
BDV is geographically more widely distributed and is also present at higher rates in
animals than previously thought. It remains unclear whether this is due to a larger
dissemination of BDV or merely to a higher interest for the virus, associated with an
improvement in the diagnostic methods 63,64.
However, many fundamental questions regarding the epidemiology of BDV
remain unsolved. Most importantly, the way of transmission and the involvement of
potential vectors remain elusive. BDV infectivity and RNA have been detected in
body secretions, suggesting that BDV could be transmitted through salival, nasal, or
conjunctival secretions, and particularly urine and faeces 65. Animals become infected
by direct contact with these secretions or by exposure to contaminated food or water.
Since direct transmission of BDV from diseased horses or sheep to uninfected animals
has not been proven, a different natural reservoir of BDV, which has not yet been
identified, must exist. Several studies suggest that rodents could be vectors.
Specifically, the urine of experimentally infected rats showed high BDV titers, and
inoculation of adult black hooded rats with BDV has been shown to induce persistent
infection in the absence of disease 66. It has also been shown that BDV in fresh urine
samples of carrier rats entered the brains of recipient rats via the olfactory route and
can cause BD. Thus, susceptible farm animals possibly acquire the virus from
persistently infected rats 67. In addition, there is evidence for horizontal transmission
via urine in the case of Lassa and Hanta virus. Interestingly recent RT-PCR and in situ
hybridisation data of BDV in a fetus from a horse with BDV infection suggests
intrauterine, i.e., vertical, transmission in nature 68. There is, however, also the
possibility that BDV is transmitted via arthropod vectors. Ticks, for example, were
already discussed as a possible vector for BDV. They are obligate, blood-sucking
members of the order Ascarina and class Arachnida and are very common agents of
vector-borne diseases; e.g., they play an important role in transmitting viruses,
bacteria, spirochetes, parasites and rickettsia. Ticks are divided into three families,
8only two of them are capable of causing infection: soft ticks (Argasidae) and hard
ticks (Ixodidae), the latter being responsible for most tick-related diseases. Ixodes
ricinus is one of the most common hard ticks in Europe and can therefore be found in
the endemic area as well. The life cycle of ticks stretches over two years and includes
egg, larva, nymph, and adult. All stages except egg require a blood meal for
morphogenesis. Lyme disease, Ehrlichiosis, Babesiosis or FSME are some examples
of tick-borne diseases 69. The idea, that ticks could be a vector for BDV is supported
by the fact that BD tends to occur in spring and early summer and is more frequent in
some years than in others. Moreover, ticks have been associated with transmission of
an equine encephalomyelitis similar to BD in the Near East 70. But BDV has never
been isolated from insects in Europe so far and it is still controversial whether BDV
can cause a viraemia, which would be required for any tick-borne infection.
BDV has gained major interest in 1985, when Rott et al. (1985) suggested that BDV
or a BDV-like virus might be associated with various human psychiatric diseases 71,
and since then the epidemiology of BDV was investigated intensively by medical and
veterinary virologists. Antibodies recognising BDV specific antigens were found in
the sera of some psychiatric patients with higher prevalence than in healthy controls.
Accumulating evidence, using various serological techniques, confirmed the original
findings and indicated that BDV infections in humans occurred worldwide and
seemed to be associated with certain human mental diseases 72-83. In general, the
highest percentage of seropositive patients could be found in areas of Germany.
Investigation of cerebral spinal fluid (CSF) from BDV-seropositive patients with
acute psychiatric episodes (mainly schizophrenia and affective psychoses) showed
intrathecally synthesised BDV-specific antibodies in 25% of patients 84. However,
solid proof for a role of BDV in human psychiatric disorders does not exist. There are
several reports about the isolation of BDV RNA from peripheral blood or brain tissue
of human psychiatric patients 85-88. These reports, however, are not totally convincing
and the human origin of most “human” BDV isolates reported so far was recently
questioned by Schwemmle et al. (1999). They showed that the genomes of such
“human” BDV isolates were closely related to BDV strains frequently used for
experiments in the various reporting laboratories 89. In conclusion, the question as to
whether a potential BDV infection of humans can induce neuropsychiatric disease and
thus whether BD can be called a zoonosis, is still controversial. Certainly all studies
9published so far have reported a significantly higher prevalence of BDV-specific
antibodies in sera and, if available, in CSF of neuropsychiatric patients when
compared to healthy humans.
2.4. Clinical manifestations
Horses and sheep with BD exhibit a variety of clinical symptoms, predominantly
behavioural abnormalities, apathy and movement disorders, which are not specific for
BD but may also be seen in animals infected with other microorganisms invading the
CNS.
The incubation period is variable, between two weeks and a few months. BDV
infections in horses are often clinically inapparent, but they can result in simultaneous
or consecutive disorders in behaviour, sensibility and motility. During the initial
phase, nonspecific signs such as hyperthermia, anorexia, and alternance of colic and
constipation are observed. During the acute phase, neurological signs result from
meningoencephalitis, such as abnormal posture, ataxia, proprioceptive deficit and
repetitive movements. These signs can be associated with abnormal reactions to
external stimuli such as hyperexcitability, aggressiveness, lethargy, somnolence and
stupor. In the final phase, paralysis can appear, followed by convulsions. Death
usually occurs after one to three weeks and the death rate in horses is above 80%, and
50% in sheep 90,56,91.  In animals that have survived the acute phase of the disease,
recurrent episodes may possibly appear for the rest of the animals life (chronic
infection) with depression, apathy, somnolence, fearfulness, in particular after stress
64,90.  However, this is still controversial. Although the clinical pattern is still
considered to represent classical BD, infection may also result in asymptomatic
carrier status, subtle disturbances in learning and memory, profound disorders of
behaviour and movement or death 24,92.
Various laboratory animals are susceptible to BDV infection. The incubation
period, mortality and severity of the disease considerably depend on the infected
animal species, viral variant and host immune status. In adult immunocompetent
animals, the infection causes a meningoencephalitis as in horses and sheep. However,
immunodepressed animals or animals with immature immune system show more
discrete symptoms. Lewis rats for example are highly susceptible to the infection and
represent an excellent model to study BD pathogenesis.
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2.5. Immunopathology
The crucial importance of the immune system in BDV infection becomes obvious
when athymic or immunocompromised animals are infected. In a detailed study the
immunopathological basis of BD was established in rats 93. It was shown, that an
infection of neonate and immunosuppressed adult rats resulted in the absence of
encephalitis and disease. The frenzied behaviour and subsequent blindness in
immunocompetent adults were therefore attributed to a uniquely transient
immunopathologic reaction targeted to centers in the limbic system and retinal
neurons 93.
BDV infection is noncytolytic and persistent. Mechanisms of pathogenicity in
the brain may include direct interaction with intracellular signaling and function, or
interference with intracellular communication essential to brain function, probably
through soluble factors such as cytokines, neurotrophins, and/or neurotransmitters
94,95.
The adult- and the neonatally infected Lewis rat models are the best-studied
systems for BDV infection. Infection of adult Lewis rats produces a prominent
neurobehavioral disorder and is characterised by pronounced immunopathology. In
the acute phase (4 to 8 weeks post infection), cellular infiltrates, such as CD4+ and
CD8+ T cells, natural killer cells and macrophages, and Th1-type cytokines are
prominent in perivascular and parenchymal regions of the CNS. In the chronic phase
(15 weeks post infection and beyond), a decline in infiltrates is accompanied by an
increase in Th2-type cytokines and a shift to humoral immune response 96. CD8+ cells
mediate destruction of virus-infected cells in the CNS, whereas CD4+ T cells promote
production of antiviral antibodies. Although antibodies to N and P generated during
the acute phase of the disease are non-neutralising 97, antibodies with neutralising
capacity increase dramatically after the acute phase 98 and likely participate in
restriction of virus to neural tissue 99.
The neonatal rat model does not show overt immunopathology; instead,
despite high virus load in the brain and lifelong persistence, animals infected within
the first 12h of life develop a mild behavioural syndrome and restricted
neuropathology that may provide a more intriguing model for neuropsychiatric
disorders. Although cellular inflammatory response to BDV following neonatal
infection is restricted, a phenomenon ascribed to the immaturity of rat postnatal
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immune function, a brief surge in mononuclear cell infiltrates occurs 100,101, along with
elevations in expression of proinflammatory cytokine 100,101, chemokine 102, and
chemokine receptor transcripts103,104.
In conclusion, BD in rats appears to be a CD4+ T-cell-dependent
immunopathological disease, in which CD8+ T-cells and/or CD8+ T-cell-mediated
cytodestructive mechanisms are operative, leading to tissue destruction, organ
atrophy, and clinically to organ dysfunction and disease 105. The similarity of
inflammation and the cellular composition of the infiltrates in ovine and equine BD
lead to the assumption that BDV infection induces the same immunopathological
process as in laboratory animals 106.
2.6. Diagnosis
Reliable intra vitam diagnosis of BD is still difficult. Horses and sheep with BD
exhibit a variety of clinical symptoms, which may be unspecific for BD and can be
caused by other CNS diseases. Increased protein content and mononuclear pleocytosis
may be seen in cerebrospinal fluid (CSF) of animals with BD. However, these
changes are not specific for BD but rather represent non-specific indicators of viral
meningoencephalitis 57. BDV specific antibodies in serum and / or CSF are better
indicators. Indirect immunofluorescence assay (IFA) appears to be the most reliable
method 34,107. However, it was shown by Caplazi et al. (1999), that antibodies could
not be found regularly in animals, which were diagnosed as BD by histology 37 and
that the prevalence in healthy sheep of the endemic area (Switzerland, Principality of
Liechtenstein) for slaughter was 6,4% 108,109. Therefore post-mortem confirmation by
histological analysis of brain tissue is required.
On a histological level, variable degrees of encephalitis are observed with BD
35,106,110. It is characterised by disseminated mononuclear meningitis and
polioencephalomyelitis with subsequent neuronal degeneration. Usually, a site
predilection for areas of the limbic system, particularly the hippocampal formation
can be noted, whereas the brain stem and cerebellum are relatively spared 106.
Traditionally, Joest-Degen inclusion bodies in nuclei of infected neurons have served
as BDV specific markers 111, but they cannot consistently be seen by routine histology
in brains of animals suffering from BD. CD4+ T cells are predominantly present at
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perivascular sites, whereas CD8+ T cells are found both in the perivascular cuffs and
in the brain parenchyma 57,106.
Immunohistological analysis of paraffin-embedded brain sections with
monoclonal antibodies against the major BDV antigens p40 and p24 consistently
showed that virus-infected cells are non-uniformly distributed in brains of diseased
animals and that antigen-positive neurons are found most frequently in the
hippocampus 35,36,106.
To improve the sensitivity of BDV antigen detection, an antigen-capture
ELISA was introduced which uses a cocktail of monoclonal antibodies and
monospecific polyclonal antiserum for antigen capture and detection, respectively 34.
Later, specific antibodies against BDV-p40 and –p24 antigens were developed and a
simple, quantitative and sensitive antigen capture ELISA system was established 29.
RT-PCR or RT-nested PCR analysis of native or formalin fixed brain tissue is
a sensitive alternative technique that may be used to confirm the clinical diagnosis of
BD 33,36,57,112-115. However, since high-sensitivity PCR technology is prone to
contamination artefacts, confirmatory laboratory diagnosis which relies exclusively on
RT-nested PCR results should not be considered definitive 24.
A possibly more reliable, though less sensitive method to detect viral
transcripts is the analysis of thin sections of paraffin-embedded brains by in situ
hybridisation using RNA probes complementary to the major transcripts of BDV
35,57,111,116,24.
The aim of the present study was to establish a more sensitive and
reproducible method for the detection of BDV from various tissues, which also allows
for quantitative comparison of virus load. We therefore used TaqMan® Real Time RT-
PCR as the method of choice. In addition we wanted to validate this method by
screening brain tissue samples from sheep and horses, which had been diagnosed as
BD by histological and immunohistochemical examinations. Finally, we investigated
the potential role of a blood sucking tick species, Ixodes ricinus, as a possible vector
for the transmission of BDV.
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3. Materials and Methods
3.1. Primers for Real Time RT-PCR (TaqMan®)
For the amplification of BDV cDNA, consensus primers and an internal
oligonucleotide as a probe were designed based on the open reading frames of p40
and p24 from the four known BDV virus strains Borna V, Borna HE/80, Borna No/98
and Borna H1766 (for alignments of p40 and p24, see results section 4.1.1. Consensus
primers).
Primers and probes used for the amplification of BDV cDNA:
p40For: 5’ GGTTTAAAACTATGATGGCAGCCTTA 3’
p40Rev: 5’ GTGGATTAAACATCTGGAGTAGTGTAGC 3’
p40 Probe: 5’ ACCGGCCATCCCATGGTGAGAC 3’
p24For: 5’ TCCCTGGAGGACGAAGAAGAT 3’
p24Rev: 5’ CTTCCGTGGTCTTGGTGACC 3’
p24 Probe: 5’ CCAGACACTACGACGGGAACGA3’
The internal probe was labelled at the 5’ end with the reporter dye FAM (6-
carboxyfluorescein) and at the 3’ end with the quencher TAMRA (6-
carboxytetramethylrhodamine). Furthermore, nuclease oligoprobes were designed
according to the following requirements, (i) a length of 20 to 40 nt, (ii) a GC content
of 40-60%, (iii) no runs of a single nucleotide, particularly G, (iv) no repeated
sequence motifs, (v) an absence of hybridisation or overlap with the forward or
reverse primers and (vi) a TM at least 5°C higher than that of the primers, to ensure
that the oligoprobe has bound to the template before extension of the primers can
occur 117.
Amplification with p40 primers yields a product of 78bp and with p24 primers of
69bp, respectively. Primers and probes were synthesised by Applied Biosystems,
Weiterstadt, Germany.
As an endogenous control, eukaryotic 18s ribosomal RNA (Applied Biosystems,
Foster City, CA, USA) was used. The probe was labeled with VICTM dye-MGB.
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3.2. Plasmids
The two plasmids pI_pPG401:p40-dHLX-ABP-6xHis and pI_pCRII-ORFI (both
kindly provided by Rolf Kocherhans, Institute of Virology, Vetsuisse-Faculty,
University of Zurich) containing the p40 ORF were used to determine the molecular
sensitivity of the system (see section 3.9. Sensitivity and Specificity).
3.3. Cell culture
MDCK cells were used to determine the cellular sensitivity of the system (see section
3.8. Sensitivity and Specifcity) and for experimental infection of ticks. Cells (ATCC
Nr. CCL-34) were grown in Iscove’s Mod. Dulbeco's Medium (Sigma chemical co.,
St. Louis, USA). To 500ml medium 50ml 10% fetal bovine serum, 12,5ml hepes
buffer (Sigma chemical co., St. Louis, USA, 1M, H0887), 5ml L-Glutamine (Sigma
chemical co., St. Louis, USA, 200mM, G7513) and 5ml Penicillin-Streptomycin
solution (Sigma chemical co., St. Louis, USA, P0781) were added. The cells were
trypsinised (Trypsin-EDTA solution, 1x, Sigma chemical co., St. Louis, USA, T3929)
and diluted twice each week and maintained at 37°C with 5% CO2. For RNA
isolation, cells were stained with trypan blue, counted in a Neubauer chamber and cell
numbers normalised. BDV-infected MDCK cells (BDV isolate of the horse H1766)
were a kind gift by Dr. S. Herzog, Institute of Virology, University of Giessen,
Germany.
3.4. Tissue samples
Ovine and equine brain samples included in this study were collected during autopsies
at the Institute of Veterinary Pathology, Vetsuisse-Faculty, University of Zurich from
the years 1996 to 2003. The brain was removed from the cranium and divided in two
halves by longitudinal section. From one halve of the brain, tissue samples (approx. 1
cm3) were collected with a scalpel, stored in small petri dishes at –20°C or –70°C,
respectively, until further use. The other halve of the brain was fixed by immersion in
4% buffered formaldehyde for at least 48 hours and then sliced according to five
standard cuts of the brain. Sections were stained in haemalaun-eosin (HE) for
microscopical examination to estimate the inflammatory reaction characterised by
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disseminated mononuclear meningitis and polioencephalomyelitis with subsequent
neuronal degeneration 106.
Specifically, samples from the cortex, hippocampus and cerebellum (or lobus
piriformis, if no cerebellum available) were collected from a total of 6 BDV-infected
animals (three sheep and three horses). As a negative control, brain samples from two
uninfected animals (one sheep and one horse) were collected.
Sheep samples:
a) BDV infected S03-0057 (Cortex, Hippocampus, Cerebellum)
S02-1736 (Cortex, Hippocampus, Cerebellum)
S99-1356 (Cortex, Hippocampus, Cerebellum)
b) Non infected S02-0857 (Cortex, Hippocampus, Cerebellum)
Horse samples:
a) BDV infected S00-0913 (Cortex, Hippocampus, Cerebellum)
S99-0598 (Cortex, Hippocampus, L. piriformis)
S96-0868 (Cortex, Hippocampus, L. piriformis)
b) Non infected S01-1038 (Cortex, Hippocampus, Cerebellum)
3.5. Immunohistochemical examination of tissue samples
Immunohistochemical examination of the brain samples was performed in parallel to
the TaqMan® PCR with slides of the animals and brain sites described above.
Formalin fixed and paraffin embedded sections were deparaffinized and rehydrated in
xylene and alcohol. Sections were then counterstained with haemalaun for 2 min and
watered for 3 to 5 min. After digestion with 0,1% Pronase (DAKO Cytomation,
Copenhagen, Denmark, S2013) for 10 min at room temperature, endogenous
peroxidase was blocked by incubation with H2O2 (3% in H2O + 0,2% in NaN3) for 10
min at room temperature. Sections were incubated with a monoclonal mouse-anti
BDV antibody, which recognises p38/40 (L. Stitz, Tübingen, Germany) in a dilution
of 1:10’000 over night at room temperature. Then sections were incubated for 10 min
at room temperature with a secondary anti-mouse/anti-rabbit-biotinylated antibody
(ChemMateTM-KIT, DAKO Cytomation, Copenhagen, Denmark, K5003). Finally,
streptavidin-peroxidase (ChemMateTM-KIT, DAKO Cytomation, Copenhagen,
Denmark, K5003) was added for 10 min at room temperature. After each step slides
were thoroughly washed with PBS (Phosphate buffer solution, pH 8.0). Finally, the
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reaction was visualised with AEC substrate (AEC-Substrate chromogen kit, Zymed,
San Francisco, CA, USA, 00-2007).
3.6. Experimental infection of ticks
Adult female ticks (Ixodes ricinus) were inoculated with BDV-infected or non-
infected MDCK cells according to the method of Burgdorfer 118. For experimental
infections, a suspension of 2 x 106 cells/ml (approx. 75% of those infected with BDV)
was used. Individual animals were fixed dorsally on adhesive foil and then a capillary
tube containing the suspension of BDV-infected MDCK cells was pushed over the
hypostome and cheliceral elements, excluding the pair of palpi. Blocks of plasticine
were used to hold the capillary in position. The whole procedure was performed with
the aid of low power magnification. The ticks were fed at room temperature for 1 to 3
hours, during which period they ingested 0.01 to 0.03 ml of the cell suspension (i.e.,
2-6 x 104 cells), which is the amount they normally take up according to Burgdorfer et
al. 118. After a waiting period of one to three hours, most of the ticks got thicker and
defecation was admitted as evidence of the absorption. The partially fed ticks, 80 to
100 ticks at a time, were removed and stored in tubes with a perforated cover to
ensure air supply. The tubes itself were kept in a small box which was lined with wet
gauze. Since it is critical to keep the animals at humid climate, blades of grass were
added in addition.
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 Fig. 2. Artificial feeding of ticks
3.7. RNA extraction and reverse transcription
Total RNA from MDCK cells and vaccine suspension (see section 3.9.1. Specificity
assay) was directly extracted with RNeasy Mini Kit (QIAGEN AG Basel,
Switzerland). The other samples were treated as follows before RNA extraction. Brain
tissue samples (approx. 30 mg/sample) were disrupted and homogenised with
QIAshredder and total RNA subsequently isolated with RNeasy Mini Kit. Ticks were
disrupted and homogenised with a mortar in 400µl RLT buffer, lysis buffer provided
with the RNeasy Mini Kit containing 10µl β-Mercaptoethanol per ml buffer, prior to
RNA isolation with RNeasy Mini Kit. RNA from all samples was then digested with
1µl RNase-free DNase (Promega, Dubendorf, Switzerland) for 1h at 37°C, followed
by a deactivation step at 95°C for 5 min.
Isolated and purified RNA was reverse transcribed into cDNA using the
Reverse Transcriptase System (Promega, Dubendorf, Switzerland). Briefly, total RNA
was incubated with random primer and 30 units RT for 1h at 42°C. Then the RT was
inactivated for 5min at 95°C. The cDNA was stored at –20° C until further use.
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3.8. PCR amplification by TaqMan® technology
PCR amplification and quantification were performed on an ABI 7700 real-time
Sequence Detection System (Applied Biosystems, Rotkreuz, Switzerland).
3.8.1. Principles
The basis for PCR quantitation in the ABI 7700 system is to continuously measure
PCR product accumulation using a dual-labeled fluorogenic oligonucleotide probe
called a TaqMan® probe. This probe is composed of a short (ca. 20-25 bases)
oligodeoxynucleotide that is labeled with two different fluorescent dyes. On the 5'
terminus is a reporter dye (FAM) and on the 3' terminus is a quenching dye
(TAMRA). This oligonucleotide probe sequence is homologous to an internal target
sequence present in the PCR amplicon. When the probe is intact, energy transfer
occurs between the two fluorophores and the quencher suppresses emission of the
reporter. During the extension phase of PCR, the probe is cleaved by 5' nuclease of
Taq polymerase thereby releasing the reporter from the oligonucleotide-quencher and
producing an increase in reporter emission intensity (see fig. 3). The ABI Prism 7700
uses fiber optic systems, which connect to each well in a 96-well PCR tray format.
The laser light source excites each well and a CCD camera measures the fluorescence
spectrum and intensity from each well to generate real-time data during PCR
amplification. The ABI 7700 Prism software examines the fluorescence intensity of
reporter and quencher dyes and calculates the increase in normalised reporter
emission intensity over the course of the amplification. The results are then plotted
versus time, represented by cycle number, to produce a measure of PCR
amplification. To provide precise quantification of initial target in each PCR reaction,
the amplification plot is examined at a point during the early log phase of product
accumulation. This is accomplished by assigning a fluorescence threshold above
background and determining the time point at which each sample's amplification
reaches the threshold (defined as the threshold cycle number or CT). Differences in
threshold cycle number are used to quantify the relative amount of PCR target
contained within each tube as described previously.
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3.8.2. Reaction conditions
PCR amplification was carried out in 25-µl reaction mixtures per well containing
12.5µl of 2x TaqMan® Universal PCR Master Mix (Applied Biosystems, foster City,
CA, USA), 600nM of each primer, 80nM (p40-56T) and 160nM (p24-54T) of the
probes, and 3,5µl of cDNA. In addition, 18s rRNA was amplified as an internal
control to monitor the quality of the extracted RNA (PE Biosystems, Warrington,
UK). The same 18s primers/probe were used for amplification of cDNA from MDCK
cells, tissues and ticks. PCR conditions were set as follows: 2 min at 50°C to activate
the Uracil-N-Glycosilase, which detects possible former PCR products and destroys
them, and then 10 min at 95°C to inactivate the Uracil-N-Glycosilase and activate the
polymerase followed by 40 cycles consisting of denaturation at 95°C for 15s and
annealing and elongation at 60°C for 1 min. The data were analysed with the
sequence detector software (version 1.7). Signals were regarded positive if the
fluorescence intensity (increase of fluorescence ΔRn) exceeded 10 times the standard
deviation of the baseline fluorescence (threshold cycle CT). CT values of 40 were
regarded as negative. The threshold cycle or CT value is the cycle at which a
statistically significant increase in ΔRn is first detected.
Fig 3. Scheme of the TaqMan® technology (TaqMan® Universal PCR Master Mix,
Protocol, Applied Biosystems, Foster City, CA, USA)
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3.9. Specificity and sensitivity assays
3.9.1. Specificity assay
To determine whether the p24 and p40 consensus primers were specifically
amplifying cDNA from BDV, total RNA from other virus species (see table 2) was
used as control template (see also 4.1.3. Specificity). Virus RNA was extracted from
vaccine suspensions containing inactivated virus using RNeasy Mini Kit. As a
positive control, brain tissue (cortex) of a sheep, dissected at the Institute of
Veterinary Pathology, Vetsuisse-Faculty of the University of Zurich, and suffering
from BD (S01-1629) was applied.
Order Mononegavirales
Family Paramyxoviridae Genus  Parainfluenzavirus 21)
Parainfluenzavirus 32)
Canine distemper virus1)
Family Rhabdoviridae Genus Lyssavirus3)
Order Nidovirales
Family Coronaviridae Genus Porcine Epidemic Diarrhoea virus 2)
1) Total RNA from vaccine solution Vetamun Live Standard, Intervet
International B. V., Boxmeer, NL
(In addition to theses two viruses, Canine Adenovirus, Canine Parvovirus,
Leptospira interrogans, Serovar Canicola and Serovar Icterohaemorrhagiae are
contained in the vaccine as well.)
2)  Total RNA from PI3 and PEDV infected cells, kind gift of the Institute of
Virology, Vetsuisse-Faculty, University of Zurich
3)  Total RNA from vaccine solution Rabdomun, ESSEX, Tierarznei, Germany
Table 2. Templates used to determine the primer specificity for BDV detection
3.9.2. Sensitivity assay
3.9.2.1. Molecular sensitivity
To determine the molecular sensitivity of the system, plasmids containing the p40
ORF (for details see section 3.2) were serially diluted by 10-fold dilution steps
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covering a range between 108 and 10-2 plasmid molecules per PCR reaction. PCR
conditions were as described in 3.7.2.
3.9.2.2. Cellular sensitivity
To determine the cellular sensitivity of the system, BDV-infected MDCK cells (and as
a control uninfected cells) were serially diluted and RNA extracted for TaqMan® PCR
(for cell culture and RNA extraction see sections 3.3 and 3.7, respectively). Briefly,
cell numbers of BDV-infected and non-infected cells were normalised by addition of
PBS. Then, BDV-infected cells were diluted with non-infected cells by 10-fold
dilution steps. The tubes were centrifuged and RNA was extracted from the pellet as
described above. Cell numbers were also monitored by amplification and
quantification of cell-specific RNA (with 18s rRNA primers, see above).
All the following calculations were performed according to the relative standard curve
method.
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4. Results
4.1. Establishment of the Real Time RT-PCR (TaqMan)
4.1.1. Consensus primers
The negative-stranded RNA genome of BDV contains 6 ORFs. The two major gene
products are the nucleoprotein p40 and the phosphoprotein p24. We designed primer
and probe sequences based on the consensus sequences of the four major BDV strains
Borna V, Borna HE/80, Borna H1766 and Borna No/98.
A
Fig. 4. Partial sequence alignment of the genomic RNA for p40 (A) and p24 (B) of the four
BDV strains. The primary sequence consensus is shown at the bottom of the alignment.
Asterisks represent identical positions. Red box: Forward consensus. Blue box: Probe
consensus. Green box: Reverse consensus.
B
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Expected p40 PCR product:
5’-
GGTTTAAAACTATGATGGCAGCCTTAAACCGGCCATCCCATGGTGAGACT
GCTACACTACTCCAGATGTTTAATCCAC-3’
Expected p24 PCR product:
5’-
TCCCTGGAGGACGAAGAAGATCCCCAGACACTACGACGGGAACGACGGG
TCACCAAGACCACGGAAG-3’
To rule out unspecific amplification of host cDNA, the expected PCR product was
used as a query sequence in a BLAST search of the non-redundant nucleotide
sequences deposited at GenBank (www.ncbi.nlm.nih.gov). This search revealed no
significant match apart from BDV for both sequences.
4.1.2. Optimisation of the Real Time RT-PCR
In an initial experiment, three different primer concentrations (5pmol/µl, 2pmol/µl
and 0,5pmol/µl) and probe dilutions (0,33pmol/µl, 0,66pmol/µl and 1,33pmol/µl)
were tested to optimise the Real Time RT-PCR reaction. As a target, brain tissue
samples (hippocampus) of a BDV infected sheep was used. Ideally, the slope in the
linear phase of increase in fluorescence should be approx. 2 3.1, reach a  plateau at
least at 1 and the CT value should be as small as possible. These criteria were best met
at primer concentrations of 5pmol/µl, and probe concentrations of 0,66pmol/µl for
p40 and 1,33pmol/µ l for p24. Accordingly, the threshold for the increase in
fluorescence over time (or cycles), ΔRn, was set as 10 –2.
4.1.3. Specificity
To determine the specificity of the two primer pairs for the detection of BDV, total
RNA from vaccine suspensions and infected cells as specified in section 3.9.1.
Specificity assay, table 1, was reverse transcribed and used as a template for TaqMan®
PCR. The results using primers and probe for p40 are shown in fig. 5. Primers and
probe for p24 gave similar results but the data are not shown. The CT values (the cycle
number at which ΔRn meets 10 –2) for all RNA viruses tested (four from the order
Mononegavirales, one Nidovirales) were 40 and therefore negative. In contrast,
24
reverse transcribed extracted total RNA from a control brain sample (cortex) of a
sheep suffering from BDV yielded a positive CT value of 17 cycles. The designed
primers were therefore regarded suitable for the specific detection of BDV.
4.1.4. Sensitivity
4.1.4.1. Molecular sensitivity
In order to establish how many DNA molecules could be detected with Real Time
RT-PCR (molecular sensitivity), a 10-fold dilution series (covering the range between
108 and 10-2 plasmid molecules per reaction) of the plasmids pI_pPG401:p40-dHLX-
ABP-6xHis and pI_pCRII-ORFI, both containing the p40 ORF, was tested. In four
independent experiments, with Real Time RT-PCR we were able to detect 10 or more
molecules per reaction (see figs. 6 and 7). In single experiments it was even possible
to detect less than 10 molecules. It was concluded that the molecular sensitivity
ranged between the detection of 1 and 10 molecules and therefore the assay proved to
be highly sensitive.
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Fig. 5. Specificity of p40 primers and probe for BDV detection. Extracted RNA from
brain tissue (BDV positive sheep) or vaccine suspensions (other RNA viruses) was
reverse transcribed and used as a template for TaqMan® PCR. Colored squares (under the
treshold): PI2 (Parainfluenzavirus 2), PI3 (Parainfluenzavirus 3), CDV (Canine distemper
virus), Lyssavirus, PEDV (Porcine Epidemic Diarrhea virus). Blue and purple squares
(curve): amplification from control sheep;  p40 primers yields a positive CT value of 17.
+ control (brain, sheep)
other RNA viruses
CT
25
Fig. 6. Molecular sensitivity as determined with a dilution series of plasmid
pL_pPG401 and primers p40. The higher the CT values, the lower the virus load. x-
axis: log plasmid number. y-axis: corresponding CT value.
Fig. 7. Molecular sensitivity as determined with a dilution series of plasmid
pL_pPVRII and primers p40. The higher the CT values, the lower the virus load. x-
axis: log plasmid number. y-axis: corresponding CT value.
4.1.4.2. Generation of relative standard curves using BDV infected MDCK
cells
As a prerequisite for the application of a BDV-specific Real Time RT-PCR, we chose
to use the relative standard curve method to compare different samples on a semi-
quantitative level. MDCK cells persistently infected with BDV were used for the
generation of relative standard curves for p40 and p24, and 18s rRNA as an
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endogenous control. Normalised infected MDCK cells were serially diluted in 10-fold
steps. From these cells, RNA was extracted and reverse transcribed as described
above. The TaqMan® results from the serial dilutions were then used to generate
relative standard curves (y = ax+b) for the virus RNA using p40 and p24 primers, and
for the host cell RNA (i.e., the total RNA used for the reverse transcription reaction)
using 18s rRNA primers and probe. The virus-specific standard curves (see figs. 8 and
9) were used as basis to normalise the signals (CT values) from p24 and p40 primer
pairs from all experimental data and account for differences in the kinetics of the PCR
reactions between the two primers (represented by differences in the slope a). A third
standard curve representing the signal from 18s rRNA primers in a dilution series of
uninfected MDCK cells (fig.10) was then used as an endogenous control to calibrate
the system (hence termed the calibrator) against differences in the efficiency of the
RNA extraction or cDNA synthesis of single experiments.
Fig 8. Relative standard curve (y= ax + b) for virus load in infected MDCK cells
using p40 primers.  The slope (a) amounts to –3.3317. (y = -3.3317x + 41.111).
x-axis: log number BDV infected MDCK cells. y-axis: corresponding CT value. The
higher the  CT values, the lower the virus load.
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Fig 9. Relative standard curve  (y= ax + b) for virus load in infected MDCK cells
using p24 primers.  The slope (a) amounts to –3.1796. (y = -3.1796x + 41.369).
x-axis: log number BDV infected MDCK cells. y-axis: corresponding CT value. The
higher the  CT values, the lower the virus load.
For all experimental samples (sheep, horse, ticks), the target quantity (p40, p24
values) was determined from the corresponding standard curve and divided by the
target quantity of the calibrator (18s rRNA). Therefore, the calibrator becomes the 1x
sample, and all other quantities are expressed as an n-fold difference relative to the
calibrator.
Fig. 10. Relative standard curve  (y= ax + b) for total RNA as represented by the
amount of 18s rRNA in a dilution series of uninfected MDCK cells. The slope (a)
a m o u n t s  t o  – 3 . 1 7 7 5 .  ( y  =  - 3 . 1 7 7 5 x  +  3 1 . 0 6 3 ) .
x-axis: log plasmid number. y-axis: corresponding CT value. The higher the CT values,
the lower the virus load.
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4.2. Application of the Real Time RT-PCR
4.2.1. Cellular sensitivity in persistently BDV infected MDCK cells
After generating relative standard curves for p40, p24 and 18s rRNA, we tested the
cellular sensitivity of the Real Time RT-PCR to detect BDV in the persistently
infected MDCK cells. BDV-infected MDCK cells were diluted in 10-fold dilution
steps and complemented with non-infected MDCK cells to obtain a uniform cell
number for RNA extraction of 106 cells. As a negative control (threshold, see fig. 11),
RNA from non-infected MDCK cells was used as a template As shown in fig.11, it
was consistently possible to detect one single infected cell in 1 million uninfected
cells, i.e., the cellular sensitivity of the Real Time RT-PCR was between 0.1 and 1.
Fig. 11. Distribution of virus load in a dilution series of MDCK cells persistently
infected with BDV. The threshold for both primers is 0.00004 (dashed line). Bars
represent the average of 2 independent experiments. x-axis: number infected MDCK
cells. y-axis: relative BDV copy number.
4.2.2. Brain tissues from BDV infected sheep and horses
Frozen brain samples from three BDV-positive sheep and horses, respectively, were
processed as described in 3.4 and analysed with TaqMan® PCR. The negative
threshold was generated from brain tissue samples from a non infected sheep and
horse (see figs. 12 and 14 and table 3). Total RNA from each tissue was extracted in
three independent experiments, and the corresponding cDNA run twice on the ABI
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Prism 7700. Finally, the CT values were processed using the relative standard curves
for p40, p24 and 18s rRNA, generated with infected (p40, p24 and 18s rRNA) MDCK
cells.
4.2.2.1. Sheep
Since the three sheep chosen for examination were diagnosed positive according to
histological and immunohistochemical data, it could be expected that the more
sensitive Real Time RT-PCR method would detect the virus as well. Indeed, all three
sheep showed presence of viral RNA in three independent brain sections measured.
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Fig. 12. Distribution of virus load in three different sheep brain sites of three BDV
infected sheep (S03-0057, S02-1736 and S99-1356). The threshold for both primers is
0.005 (dashed line). x-axis: brain sites cortex, hippocampus and cerebellum. y-axis:
relative BDV copy number.
Real Time RT-PCR Immuno-
histochemical
examination
Sheep Brain site
Primer p40
(Relative BDV copy
number per cell)
Primer p24
(Relative BDV copy
number per cell)
p38/40
S03-0057 Cortex (*) 74.4295436 254.158648 ++
Hippocampus 65.1576734 851.437847 +++
Cerebellum 0.76140349 2.48873949 +
S02-1736 Cortex 0.07496186 0.54094983 +
Hippocampus 0.32448315 5.46036848 +
Cerebellum 0.008218 0.00594945 -
S99-1356 Cortex 23.6624731 1678.44101 +++
Hippocampus 13.0346773 444.378386 +++
Cerebellum 0.00985846 0.50818802 + - ++
S02-0857 Threshold 0.00506513 0.0051369 -
Table 3. Results, normalised and calibrated, of the three BDV infected sheep.
Threshold of the results of the negative control (sheep S02-0857). Values represent
the average  from three independent experiments, except those marked with an
asterisk (*) (only one experiment). Immunohistochemical examination: No antigen (-)
or low (+), moderate (++) and large amount (+++) of BDV antigen detected.
The threshold of 0.005 (both, p40 and p24) represented the average relative BDV
copy number of three samples each from cortex, hippocampus and cerebellum from a
BDV negative sheep, as diagnosed by immunohistochemical methods (see fig. 13).
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Therefore, values below 0.005 were considered negative. Notably, virus loads in the
three positive sheep were consistently lower in the cerebellum compared to cortex and
hippocampus. Interestingly, a much lower BDV load was observed for sheep S02-
1736 than for the other two; this result was also confirmed by the
immunohistochemical data (see table 3).
Furthermore, CT values generated with primers and probe for p40 were higher than
those generated with primers and probe for p24, suggesting higher transcription levels
for phosphoprotein p24 compared to the nucleoprotein p40.
4.2.2.2. Horses
Frozen brain samples of three horses suffering from BD were tested for the presence
of BDV RNA as well (see figs. 13 and 14 and table 4). For one horse, S00-913, the
same three brain tissues as from the sheep were analysed. However, for the other two
horses, no cerebellum samples were available, but lobus piriformis instead.
Consequently, lobus piriformis was used for the analysis in addition to tissues from
the cortex and the hippocampus for these two horses. The negative threshold of
0.0004 (for both, p40 and p24) was calculated as for the sheep, using the CT values
from cortex, hippocampus and cerebellum of a BDV negative horse for the analysis.
In the BDV positive horse S00-913, BDV load in the cortex and hippocampus were
again higher than in the cerebellum, supporting the trend from the three sheep. In the
other two cases, in contrast, lobus piriformis showed similar (S96-868) or even higher
(S99-0598) BDV load than in the cortex or hippocampus. This may be explained by
the fact that the lobus piriformis belongs to the bulbus olfactorius, which is assumed
to be the host entry point for the virus. In general, the three horses showed higher
maximum BDV load (approx. 10-fold) than the sheep, combined with a lower
background (also approx. 10-fold).  In accordance with the results of the three BDV
infected sheep, transcription levels of p24 appear to be higher than those of p40.
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Fig. 13. Immunohistochemical examination. Hippocampus of a horse (S00-0913)
suffering from BD, p38/40, magnification 100x. Circle: Intranuclear reaction (Joest-
Degen inclusion body), arrow: Cytoplasmic reaction in a BDV infected neuron.
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Fig. 14. Distribution of virus load in three different brain sites of three BDV infected
horses (S00-0913, S99-0598 and S96-0868). The threshold for both primers is 0.0004
(dashed line). x-axis: brain sites cortex, hippocampus and cerebellum or lobus
piriformis. y-axis: relative BDV copy number.
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Real Time RT-PCRHorse Brain site
Primer p40
(relative BDV copy
number per cell)
Primer p24
(relative BDV copy
number per cell)
Immuno-
histochemical
examination
S00-0913 Cortex (**) 43.6613061 10938.4734 +++
Hippocampus
(**)
3.89402325 7296.1528 +++
Cerebellum 0.22276789 82.6800901 -
S99-0598 Cortex 0.05586269 0.6373934 -
Hippocampus
(**)
2.20686871 8.60967767 ++
L.piriformis 568.546009 10378.2222 Not available
S96-0868 Cortex 8.31192757 12798.0021 +++
Hippocampus 6.29523072 2008.15664 +++
L.piriformis 57.6033 14248.2219 Not available
S01-1038 Threshold 0.00038879 0.00039515 -
Table 4. Results, normalised and calibrated, of the three BDV infected horses.
Threshold of the results of the negative control (horse S01-1038). Numbers represent
the average from three independent experiments, except those marked with two
asterisks (**) (only two experiments). Immunohistochemical examination: No antigen
(-) or low (+), moderate (++) and large amount (+++) of BDV antigen detected.
4.2.3. Experimental infection of ticks
In six independent experiments, a total number of approx. 500 ticks were fed with a
suspension containing 2 x 106 MDCK cell/ml (approx. 75% of these cells were
infected), of which they ingested not more than 10 to 30µl (i.e., 2 – 6 x 104 cells) as
described by Burgdorfer et al. (1957) 118. A total number of 150 Ixodes ticks were
included in this study (93 ticks, fed with BDV infected MDCK cells and 46 control
ticks, fed with non infected MDCK cells). Starting one day post-infection, at least 4
ticks (and at least two control ticks, fed with non infected MDCK cells; see threshold
in figs. 15 and 16) were used per time point for RNA extraction and subsequent
analysis of the virus load by TaqMan® PCR. While we were not able to keep the ticks
of experiments 1-4 alive for more than 10 to 15 days post-infection, individual
animals of experiment 5 and 6 survived up to 30 days.
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Fig. 15. Average virus load in BDV infected ticks at different time points post
infection. The threshold for both primers is 0.004 (dashed line). x-axis: days post
infection. y-axis: relative BDV copy number.
The combined data in figure 15 clearly show that virus load per tick gradually
decreased over time after ingestion of BDV-positive MDCK cells, reaching
background levels between 10 and 25 days post-infection. Furthermore, the relative
BDV copy number of the nucleoprotein p40 is clearly higher than that of p24. In
figure 16 the trend of all experiments is shown. The threshold of both primers is
0.004. Approx. 15 days post infection the signal is below the threshold and should
therefore be considered negative. The difference in virus load between single
experiments and individual ticks may be explained by the extremely low overall BDV
levels, which were likely at the limits of detection.
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Fig. 16. Average virus load in BDV infected ticks at different time points post
infection: trendline. The threshold for both primers (blue p40, red p24) is 0.004.
Approx. 15 days post infection the signal is below the threshold, i.e., the ticks are
considered to be negative. x-axis: days post infection. y-axis: relative BDV copy
number.
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5. Discussion
In the present thesis we have successfully established TaqMan® Real Time RT-PCR
for the detection of Borna Disease virus from various sources.
Although a number of PCR-based diagnostic methods for the detection of
BDV already exist, the establishment of Real Time RT-PCR has brought a number of
advantages. For example, the use of fluorescent dye-labelled probes increases the
sensitivity of detection. But the major advantage is the determination of the CT value
within the logarithmic phase of amplification reaction rather than an endpoint
determination of conventional PCR. Hence, the majority of diagnostic PCR assays
reported to date have been used in a qualitative, or “yes/no” format. A main problem
facing the diagnostic application of PCR is the production of false-positive results
attributable to contaminating nucleic acids, particularly in the form of previously
amplified material (carry-over). Any contaminant, carried over from the previous
PCR procedure or from a strongly positive sample (contamination) may be multiplied
and give false-positive results. In the TaqMan® system, the problem of carry-over is
significantly reduced due to the real-time measuring principle, so described as
“closed” or homogenous system, which makes it unnecessary to open the tubes after
amplification and requires no post-PCR manipulation 119, 120. Furthermore, cDNA from
a former amplification is being destroyed by the Uracil-N-Glycosylase provided in the
TaqMan® Universal Master Mix (Applied Biosystems, Foster City, CA, USA). This
enzyme recognises the dUTP of any possible former cDNA product and destroys
them in the first stage of the PCR. Therefore, it is not surprising that Real Time RT-
PCR has gained increasing interest in virology, including studies on flaviviruses,
hepadnaviridae, herpesviruses, orthomyxoviruses, parvoviruses, papovaviruses,
paramyxoviruses, picornaviruses, retroviruses and TT virus 120.
TaqMan® Real Time RT-PCR was also used to investigate viral dynamics in
the central nervous system of neonatally BDV infected gerbils 121. With this
exception, all previous studies have used conventional PCR approaches for the
diagnosis of BDV, i.e., the results were qualitative and with only a limited value for
quantitation. However, the paralleled investigation of the same brain sites of the
chosen animals by immunohistochemical examination showed, that the results are
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comparable and that immunohistochemistry was almost as sensitive as our PCR
results. Anyhow, the investigation with Real Time RT-PCR allows an exact and
objective evaluation of the results whereas the analysis of immunohistochemical
examination by asterisks remains subjective and certain diversity in interpretation
cannot be excluded.
For the establishment of TaqMan® Real Time RT-PCR, we initially optimised
the PCR reaction with series of dilutions of primers and probes for p40 and p24 and
subsequently determined the specificity by using a number of other RNA viruses as a
template. The primer and probe sequences for p40 and p24, respectively, were
designed based on the consensus sequences of the four BDV strains Borna V, Borna
HE/80, Borna H1766 and Borna No/98 (see section 4.1.1. Consensus primers).
However, it should be noted that strain No/98, which is only approx. 80% identical to
the other three BDV strains, might be missed with this primer/probe combination,
since No/98 differs in one nucleotide position compared to forward primer of p40, the
probe and the reverse primer of p24, respectively (see fig. 4). To confirm that we can
indeed detect No/98 or other BDV variants, samples specifically infected with Borna
No/98 should be used as a template. The TaqMan® output file from this experiment
(see section 4.1.3. Specificity, fig. 5.) demonstrated that the primers specifically
amplified BDV, while amplification of other templates yielded only background CT
values (CT = 40). This initial experiment also confirmed our setting of the threshold
cycle (CT) at ΔRn = 0.02, since all reactions with virus templates other than BDV
showed a CT value of 40 while amplification of BDV resulted in a CT value of 17. We
then measured the molecular sensitivity of the PCR reaction by using a dilution series
of two plasmids containing the p40  ORF as a template. These experiments
demonstrated that the system was able to detect between 1 and 10 plasmid molecules
per reaction and thus were extremely sensitive.
The previous study by Watanabe et al. (2001) applying TaqMan® PCR for the
detection of BDV used the absolute standard curve method by synthesising p40 and
p24 cDNA from in vitro transcribed RNAs and diluting it in uninfected host cell
tissues 121. In contrast, we chose the relative standard curve method to compare
relative virus load in different cell types. Specifically, we generated relative standard
curves by using persistently infected MDCK cells as a template for a dilution series
and host cell 18s rRNA as an endogenous control (see section 4.1.4.2. Generation of
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relative standard curves using infected MDCK cells, fig. 8 to 10). These standard
curves were then validated by measuring the cellular sensitivity to detect BDV in
infected MDCK cells. Here, it was consistently possible to detect one BDV infected
MDCK cell in 106 non-infected cells. Since the cell numbers were normalised to 106,
relative BDV copy numbers per cell (or: relative virus load) should actually be
multiplied by the factor obtained from the ratio of BDV-infected cells to non infected
cells in which the former were diluted to get the relative virus load per cell. For
example, the relative virus load of approx. 10 in 10’000 BDV infected MDCK cells
should be multiplied by 100 (106  divided by 10’000), which results in a relative virus
load per cell of approx. 1’000. In a recent study, RT-PCR was performed to estimate
the copy number of genomic BDV RNA per infected host cell 122. Specifically, either
RNA extracted from BDV infected MDCK cells, or as an internal standard in vitro
transcribed RNA from plasmid DNA containing the p40 ORF (allowing the
estimation of an absolute virus load), was used as a template for the reaction.
Applying this method, the absolute virus load per cell was estimated approx. 100 per
cell. Our calculated relative virus load of approx. 1000 per cell was therefore 10 times
more sensitive.
Having established and validated the method, we applied TaqMan® Real Time
RT-PCR to detect BDV in brain tissues of the two major hosts, i.e., horses and sheep.
The brain sites cortex and hippocampal formation were chosen according to the
predilection sites of BDV in the brain. As expected, the relative virus loads in cortex
and hippocampus were clearly higher than in the cerebellum, which is usually also
less affected by the infection. Interestingly, the relative virus loads in lobus piriformis
were higher than in cortex and hippocampus. This could be explained by the fact, that
lobus piriformis belongs to the olfactory bulb, which is a potential entry point of the
virus. However, since lobus piriformis is in close proximity to the hippocampal
formation, there is a certain possibility that samples could include parts of
hippocampal formation as well. But the data obtained by TaqMan® Real Time RT-
PCR generally supported the immunohistochemical examination of higher virus load
in cortex and hippocampus compared to the cerebellum. For future studies, it could be
very interesting to measure absolute virus loads in different brain locations and hosts
during the course of infection by establishing the absolute standard curve method.
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An interesting observation made from the TaqMan® data is the different
p24:p40 ratios seen in the various cell types. Specifically, infected MDCK cells and
tissue samples from BDV infected horses and sheep showed a high p24:p40 ratio,
while experimentally infected ticks had higher p40 values than p24. It should be
noted, however, that the used random primers amplify both, genomic and mRNA, and
therefore p40 and p24 levels reflect the sum of these two RNA populations. It has
been known since a while that p40 and p24 specific antibodies are the major BDV
components since they can also be detected in the sera of infected animals 123. In
addition, they are the main products in BDV infected cultured cells and were detected
in brain samples from BDV infected animals by immunohistochemical techniques and
western blot 124,125. Interestingly, the ratio between p24 and p40 appears to change in
the course of infection in that acutely infected cells show a higher level of p40
antigen, while persistently infected cells show higher levels of p24 29. Moreover, other
studies demonstrated that virus replication was optimal when p40 antigen was in a 30-
fold excess over p24, while the ratio of the transcript levels alone did not have an
effect on polymerase activity 30-32. Taken together, these studies strongly suggested
that the stochiometry of p40 and p24 is critical for the regulation of the BDV
replication cycle. While all these studies used in vitro systems, our data demonstrate
for the first time similar p24:p40 ratios in sheep and horses naturally infected with
BDV, which might argue for a persistent infection. The data are also in accordance
with previous evidence that a specific ratio between the p40 and p24 homologues of
other Mononegavirales including Paramyxoviruses is necessary for viral replication in
infected cells 126-128.  Assuming that the high p24:p40 ratio (N:P) in cells persistently
infected with BDV (and other viruses) would be highly unfavourable for virus
replication (specifically also for incoming viruses), control of polymerase activity
with a well-balanced ratio of the polymerase complex components P and N could be a
strategy for superinfection exclusion 31. Hence, it could be very fruitful for future
experiments to determine these ratios during the course of infection in cell lines,
experimentally infected mammalian hosts as well as potential vectors (see also below)
as a potential means to measure the stage of infection.
As a second application of the TaqMan® Real Time RT-PCR, we chose to
experimentally infect a potential vector and monitor the virus load over time. The
choice of the tick Ixodes ricinus was based on the fact that it occurs in the endemic
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BD areas, is a known vector of other virus-based diseases and has previously been
proposed as a vector for the transmission of BD-like encephalomyelitis 70. We used
capillary artificial feeding of ticks which was first described by Burgdorfer and co-
workers 118 and since then used and advanced by different groups to study ticks as a
vector for Borrelia, Ehrlichia, Rickettsia, Escherichia coli and Bacillus subtilis 129-133.
It is obvious from our six independent experiments that infected cells could be
detected over a period of one through 24 days post feeding. However, in the course of
this time the virus load per tick decreased close to background or threshold level of
0.004 (see section 4.2.3. Experimental infection of ticks, figs. 15 and 16), indicating
that the infection was probably not transmitted from the infected cells to the ticks. The
differences in the detected relative BDV copy number may be explained by the
irregular feeding habits during artificial feeding, since it was nearly impossible to get
uniformly infected ticks for experimental studies. In addition, BDV copy numbers and
18s rRNA used for calibration were measured per whole tick, i.e., differences in BDV
load in various tissues/organs could not be detected with this approach. Still, it is
theoretically possible that BDV accumulates in a specific subcompartment of the tick.
This would also explain the reversed p40:p24 ratios compared to the data from sheep
and horse tissues, and argue for BDV replication in ticks, i.e. an acute phase BDV
infection. Altogether, these observations do not necessarily argue for or against ticks
being vectors for BDV, but our experiments indicate that the newly established Real
Time RT-PCR may provide a useful tool for detecting such vectors in endemic areas.
Possible alternative strategies to test the general hypothesis that transmission of BDV
is arthropod-based could include random testing of arthropod samples from the
endemic areas for the presence of BDV. It is still controversial whether viraemia
occurs in BDV affected animals, which would be essential for an incorporation of the
virus during blood feeding on hosts.
In summary, we present here the successful establishment of TaqMan® Real-
Time PCR for the detection of Borna Disease virus. The primers detect BDV with
high specificity and the approach also proved highly sensitive to detect both plasmids
containing the p40 ORF and BDV from infected MDCK cells. In addition, Real Time
RT-PCR allowed the relative quantification of virus load from different sheep and
h o r s e  brain sites. These data were in good agreement with previous
immunohistochemical studies using the same samples. Furthermore, our data
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demonstrate that the Real Time RT-PCR approach is a valuable diagnostic and
epidemiologic tool, which allows for comparative studies using infected samples from
various sources, e.g., different tissues, body fluids and excretions (i.e., liquor, serum,
urine) and detecting possible vectors in endemic areas.
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7. Abbreviations
A Adenine
AEC Aminoethyl Carbazole
Approx. Approximately
BD Borna Disease
BDV Borna Disease Virus
C Cytosine
cDNA Complementary DNA
CNS Central nervous system
CSF Cerebro spinal fluid
CT Threshold cycle
DNA Deoxdyribonucleic acid
dUTP 2'-deoxyuridine 5'-triphosphate
ΔRn Increase in fluorecence of the reporter dye
FAM Reporter dye, 6-carboxyfluorescein
G Guanine
G-protein Glycoprotein
HE Haemalaun-eosin
H2O Water
H2O2 Hydrogen peroxide
L-protein Polymerase
M-protein Matrix protein
MDCK Madin and Darby canine kidney cells
NaN3 Sodium azide
NNS RNA Negative nonsegmented single-stranded
N-protein Nucleoprotein (N)
nt Nucleotide
ORF Open reading frame
PBS Phosphate buffer solution
PEDV Porcine epidemic diarrhoea virus
PCR Polymerase chain reaction
PI2 Parainfluenzavirus 2
PI3 Parainfluenzavirus 3
P-protein Phosphoprotein (P)
RNA Ribonucleic acid
mRNA Messenger RNA
RT Room temperature
RT PCR Reverse transcription polymerase chain reaction
T Thymine
TM Temperature
TAMRA Quencher dye, 6-carboxytetramethylrhodiamine
Taq Thermus aquaticus
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IMDCK+ p40 p24 18s rRNA
Number of
cells
1. Result 2. Result average
normalized
average
calibrated
1. Result 2. Result average
normalized
average
calibrated
1. Result 2. Result average
normalized
10000.00 23.14 23.22 296583.65 8.04159 22.45 23.02 7407.89 20.08470 16.99 16.22 36881.21
10000.00 19.51 19.48 378431.7 10.28718 19.38 20.24 6326113.4
0
17.19440 12.96 13.98 367917.18
10000.00 17.89 17.82 11759571 2.36309 18.73 18.65 13578143 2.72853 10.19 9.47 4976349.7
0
1000.00 25.92 25.63 49576.59 0.94743 25.20 25.24 119946.15 2.29222 16.33 15.85 52327.54
1000.00 23.63 23.91 198118.12 42.61532 24.54 24.13 230168.51 49.50937 19.06 19.88 4648.99
1000.00 24.42 24.22 135160.55 0.53582 26.47 25.54 71816.78 0.28470 12.95 20.08 252251.12
100.00 30.58 30.93 1590.508 0.03086 30.62 30.48 2530.39 0.04909 16.56 15.74 51547.20
100.00 28.42 28.36 8096.7059 0.01252 29.75 29.44 5078.22 0.00785 12.44 12.78 646670.25
100.00 33.21 34.37 360.7561 0.00471 34.37 34.16 171.99 0.00225 15.30 15.84 76578.35
10.00 34.11 33.41 203.70829 0.00597 34.68 33.35 229.82 0.00673 17.22 16.26 34150.00
10.00 32.89 32.57 405.7201 24.44721 33.37 33.80 284.02 17.11403 26.23 40.00 16.60
10.00 34.78 34.56 105.8145 0.00205 37.00 37.25 21.70 0.00042 15.13 25.02 51715.95
1.00 36.94 35.63 38.160139 0.00181 40.00 40.00 2.69 0.00013 16.37 40.00 21039.99
1.00 36.10 40.00 20.961712 0.00002 40.00 38.62 5.01 0.00001 40.00 11.15 924371.36
1.00 40.00 38.04 6.4634635 0.00010 40.00 40.00 2.69 0.00004 15.62 15.92 65382.85
0.10 40.00 40.00 2.651597 0.00003 40.00 40.00 2.69 0.00003 15.99 15.17 77909.67
0.10 35.44 40.00 32.310561 0.00044 40.00 40.00 2.69 0.00004 17.47 14.85 72781.93
0.10 40.00 40.00 2.651597 0.00006 40.00 40.00 2.69 0.00006 15.93 16.96 42661.72
Table A. TaqMan® results of BDV infected MDCK cells diluted in non infected MDCK cells.
Annex
II
Sheep Brain site P40 P24 18s r RNA
1. Result 2. Result average
normalized
average
calibrated
1. Result 2. Result averaga
normalized
average
calibrated
1. Result 2. Result average
normalized
S03-0057 Cortex (1) 26.54 26.01 36516.068 2738.494 25.11 25.32 120716.76 9053.06 40.00 40.00 13.33436
Cortex (2) 14.47 14.72 116666266 74.42954 13.96 14.09 398386704 254.1586 10.89 10.75 1567472.6
(BDV) Cortex (3) 19.50 19.33 4155070.7 311606.3 15.97 15.97 97299747 7296919 40.00 40.00 13.33436
Hippoc. (1) 23.14 22.97 333737.82 84.64315 19.68 20.01 5922402.8 1502.05 19.08 19.08 3942.8805
Hippoc. (2) 23.11 23.51 280239.04 1.203572 22.13 22.37 1034328 4.442235 13.42 13.48 232839.53
Hippoc. (3) 22.65 22.41 481319.97 109.6263 20.02 20.37 4600514.9 1047.822 19.46 18.55 4390.552
Cereb. (1) 29.36 29.50 4019.5837 1.421788 28.05 27.97 15909.41 5.627399 19.54 19.54 2827.1336
Cereb. (2) 28.28 28.28 8913.581 0.132659 26.99 27.23 30631.209 0.455876 15.19 15.14 67191.929
Cereb. (3) 28.67 28.64 6876.4493 0.729764 28.29 28.28 13031.244 1.382943 17.53 18.34 9422.8362
S02-1736 Cortex (1) 28.81 29.11 5583.0704 0.112207 28.09 28.09 15007.608 0.30162 16.25 15.13 49756.754
Cortex (2) 28.61 28.75 6757.335 0.045746 27.72 27.26 23496.922 0.159071 14.00 14.16 147713.4
(BDV) Cortex (3) 26.98 26.88 22740.211 0.66932 25.25 26.54 81732.991 0.240568 12.86 13.00 339750.75
Hippoc. (1) 25.34 25.29 69545.877 0.209107 22.28 22.36 979912.59 2.946356 12.69 13.29 332584.62
Hippoc. (2) 27.09 27.22 19429.053 0.469993 23.62 23.92 344770.57 8.340073 15.35 16.59 41339.035
Hippoc. (3) 24.75 25.36 84599.341 0.294349 21.65 21.89 1464268.4 5.094677 13.21 13.11 287411.44
Cereb. (1) 40.00 40.00 2.657339 0.000353 35.30 36.35 59.466859 0.007897 19.99 17.43 7530.3521
Cereb. (2) 36.92 38.57 14.734242 0.024196 40.00 40.00 2.6949909 0.004426 22.37 21.21 608.96563
Cereb. (3) 40.00 36.52 16.236401 0.000106 33.34 34.31 250.54124 0.00163 13.94 14.11 153752.6
S99-1356 Cortex (1) 22.98 24.04 256492.45 13.11569 18.39 17.98 19781147 1011.505 16.67 17.10 19556.159
Cortex (2) 20.01 19.52 3314493.7 27.65392 15.51 15.66 128776428 1074.424 14.06 14.76 119856.21
(BDV) Cortex (3) 23.41 23.80 228375.75 30.21782 17.99 18.02 22290496 2949.394 18.08 18.29 7557.6528
Hippoc. (1) 31.76 31.92 757.49627 0.892086 27.15 26.60 36896.973 43.44527 21.01 21.44 849.12963
Hippoc. (2) 25.30 24.20 111462.11 16.73734 19.86 19.87 57955858 870.3158 18.10 18.67 6659.4887
Hippoc. (3) 34.08 32.46 329.05638 21.47461 29.08 29.47 6425.9746 419.3667 28.00 28.08 15.323044
Cereb. (1) 32.82 31.14 813.83796 0.003981 27.56 27.14 25944.658 0.126893 13.68 13.58 204452.32
Cereb. (2) 33.32 32.98 308.1799 0.020505 27.70 27.76 19482.1 1.296232 17.14 17.33 15029.791
Cereb. (3) 32.35 31.83 648.92571 0.00509 28.19 28.41 12931.292 0.101433 14.07 14.53 127485.48
S02-0857 Cortex (1) 40.00 40.00 2.657339 0.001183 40.00 40.00 2.6949909 0.0012 19.56 20.24 2245.9756
Cortex (2) 40.00 40.00 2.657339 0.000349 40.00 40.00 2.6949909 0.000354 18.17 18.17 7618.0989
(control) Cortex (3) 40.00 40.00 2.657339 0.000505 40.00 40.00 2.6949909 0.000512 19.15 18.33 5266.3745
Hippoc. (1) 40.00 40.00 2.657339 0.010071 40.00 40.00 2.6949909 0.010214 22.85 22.85 263.85563
Hippoc. (2) 40.00 40.00 2.657339 5.88E-06 40.00 40.00 2.6949909 5.96E-06 13.95 11.85 452088.15
Hippoc. (3) 40.00 40.00 2.657339 1.29E-05 40.00 40.00 2.6949909 1.15E-05 13.46 13.41 235367.19
Cereb. (1) 40.00 40.00 2.657339 0.022785 40.00 40.00 2.6949909 0.023108 23.14 27.81 116.62691
Cereb. (2) 40.00 40.00 2.657339 0.005611 40.00 40.00 2.6949909 0.005691 22.35 21.76 473.58032
Cereb. (3) 40.00 40.00 2.657339 0.220051 40.00 40.00 2.6949909 0.223169 38.75 36.20 12.075994
Table B. TaqMan® results from three BDV infected and one non infected sheep.
III
Horse Brain site P40 P24 18s r RNA
1. Result 2. Result average
normalized
average
calibrated
1. Result 2. Result averaga
normalized
average
calibrated
1. Result 2. Result average
normalized
S03-0913 Cortex (1) 24.19 24.13 150636.59 0.08953 14.39 14.48 295874408 175.8505 11.28 11.28 1682533.8
Cortex (2) 32.63 33.06 376.56213 28.1829 24.42 24.63 198964.69 14891.04 27.93 27.15 13.36137
(BDV) Cortex (5) 24.71 24.86 97910.298 59.13971 19.28 18.62 11565701 6985.907 20.96 20.72 1655.5761
Hippoc. (1) 30.58 31.02 1548.3221 6.845851 20.44 20.96 3222228.4 14246.97 23.33 23.89 226.16941
Hippoc. (2) 24.57 24.16 132023.5 0.942195 16.90 16.97 48389808 345.3375 14.72 14.70 140123.26
Hippoc. (5) 32.91 33.14 329.91615 78.97237 24.68 23.88 246914.55 59104.19 29.09 29.09 4.1776149
Cereb. (1) 29.17 28.71 5605.2871 0.003415 21.69 22.19 1310979.5 0.79876 11.27 11.36 1641268.9
Cereb. (2) 37.20 37.75 15.4588 0.144844 28.90 29.34 7208.7492 67.54345 24.22 25.18 106.72758
Cereb. (5) 36.84 36.58 25.86675 0.520045 28.92 28.70 8938.0829 179.6981 25.77 25.58 49.739452
S99-0598 Cortex (1) 28.48 28.42 7767.8269 0.013134 27.69 26.99 26668.184 0.045092 13.18 12.38 591410.84
Cortex (2) 29.39 29.45 3973.3505 0.050632 27.10 27.63 25839.022 0.329266 15.51 15.51 78474.501
(BDV) Cortex (5) 29.98 30.45 2323.5362 0.103821 26.82 27.08 34416.671 1.537821 17.77 16.86 22380.15
Hippoc. (1) 20.31 20.00 2412199.6 0.760214 19.57 19.56 7202266.6 2.269823 10.44 10.37 3173052.1
Hippoc. (2) 22.20 22.17 589726.91 3.653523 21.07 21.08 2413052.1 14.94953 14.54 14.49 161413.21
Hippoc. (5) 29.19 28.96 5058.0662 348.3916 25.74 26.43 66116.461 4553.997 27.27 27.48 14.518336
L. pirif. (1) 19.16 19.18 4737851 3.116492 19.05 18.75 11726527 7.713544 11.43 11.41 1520251.4
L. pirif. (2) 20.80 20.80 1535788.1 11.31617 19.05 19.27 9687625.3 71.38149 14.39 15.25 135716.21
L. pirif. (5) 18.68 18.80 6382745.8 1691.205 15.64 15.79 117206239 31055.57 19.62 19.78 3774.0809
S96-0868 Cortex (1) 19.11 19.26 4695177.1 2.319828 14.59 14.65 258699687 127.8202 11.83 10.52 2023933.7
Cortex (2) 30.62 30.66 1709.7224 19.5058 20.98 20.36 3317350.4 37846.82 26.12 24.25 87.652016
(BDV) Cortex (5) 24.60 23.54 171141.63 3.110159 17.60 18.44 23076097 419.3622 15.81 16.22 55026.656
Hippoc. (1) 23.65 24.96 150442.96 0.281931 16.92 16.99 47694006 89.37894 12.57 13.24 533615.7
Hippoc. (2) 23.39 23.13 281656.63 8.502898 15.56 15.83 119308864 3601.801 16.59 16.82 33124.782
Hippoc. (5) 22.18 21.87 662427.28 10.10086 15.32 15.37 153020102 2333.29 15.68 15.84 65581.256
L. pirif. (1) 20.56 21.01 1570591.4 4.181665 15.82 15.61 117372074 312.5006 13.23 13.48 375589.95
L. pirif. (2) 25.36 24.65 86527.639 6.478982 17.13 17.08 42777928 3203.109 18.25 17.71 13355.129
L. pirif. (5) 21.58 22.24 731756.11 162.1493 15.08 15.21 177035055 39229.06 19.13 19.87 4512.8553
S01-1038 Cortex (1) 40.00 40.00 2.651597 2.73E-06 40.00 40.00 2.6949909 2.78E-06 12.10 11.98 970940.1
Cortex (2) 40.00 40.00 2.651597 0.000387 40.00 40.00 2.6949909 0.000393 19.17 18.63 6856.6548
(control) Cortex (5) 40.00 40.00 2.651597 0.001772 40.00 40.00 2.6949909 0.001801 21.68 20.51 1496.1159
Hippoc. (1) 40.00 40.00 2.651597 3.16E-05 40.00 40.00 2.6949909 3.21E-05 15.65 15.22 83865.206
Hippoc. (2) 40.00 40.00 2.651597 0.000114 40.00 40.00 2.6949909 0.000116 18.06 16.66 23234.875
Hippoc. (5) 40.00 40.00 2.651597 115.2094 40.00 40.00 2.6949909 117.0948 36.19 36.35 0.0230155
Cereb. (1) 40.00 40.00 2.651597 0.000121 40.00 40.00 2.6949909 0.000123 17.38 17.17 21903.645
Cereb. (2) 40.00 40.00 2.651597 0.000453 40.00 40.00 2.6949909 0.000461 19.36 18.87 5847.8705
Cereb. (5) 40.00 40.00 2.651597 0.000228 40.00 40.00 2.6949909 0.000232 24.00 17.20 11613.641
Table C. TaqMan® results fromthree BDV infected and one non infected horse.
IV
Ticks
(part I.)
p40 p24 18s rRNA
Experiment Day 1. Result 2. Result average
normaluzed
average
calibrated
1. Result 2. Result average
normaluzed
average
calibrated
Result calibrated
I. 1 35.40 37.05 42.037108 0.613639 36.25 38.19 25.364541 0.3702603 25.23 68.504627
1 33.77 33.72 199.98263 0.0046167 34.22 33.29 262.30852 0.0060555 16.33 43317.566
1 35.08 34.50 99.069202 0.0175234 37.50 36.92 20.774651 0.0036746 19.14 5653.547
1 35.40 34.83 79.085441 0.0073132 35.50 36.07 58.261354 0.0053876 18.24 10814.065
6 36.13 34.87 65.177323 0.00002401 35.40 36.30 57.334537 0.00002112 10.62 2714402.7
6 35.47 36.44 45.872866 0.00001176 38.93 36.47 20.291675 5.203E-06 10.12 3899695.4
6 32.34 33.08 422.30533 0.0001734 32.99 33.00 430.19708 0.0001767 10.77 2434822.7
6 40.00 40.00 2.651597 0.0002068 40.00 40.00 2.6949909 0.0002102 18.01 12821.726
10 37.27 37.80 14.811986 0.00001139 39.95 39.34 3.5703851 2.745E-06 11.63 1300890.5
10 34.85 33.72 148.30258 0.00005027 35.86 35.32 66.953545 0.00002269 10.50 2950300.5
10 35.11 33.85 131.90053 0.0188402 37.73 36.47 24.340746 0.0034767 18.84 7001.0195
10 37.18 34.72 60.271661 0.0042319 37.98 40.00 7.1662139 0.0005032 17.86 14242.291
II. 1 32.25 32.62 498.49435 0.000435 32.25 33.39 530.51385 0.0004629 11.81 1145950.9
1 30.73 30.00 2133.5276 0.0033123 30.16 29.95 3627.1333 0.0056311 12.61 644123.75
1 32.02 33.02 494.35272 0.0003683 32.07 32.10 831.55266 0.0003428 10.78 2426016.7
1 34.70 34.16 126.71974 0.0005155 34.25 34.60 153.95746 0.0001725 12.16 892462.73
III. 1 36.51 35.80 38.9506759 0.00034424 37.17 37.25 20.3333224 0.0001797 15.01 113151.036
1 29.59 29.48 3671.64175 0.01126474 30.16 30.27 3223.53817 0.00988994 13.55 325941.2
1 34.53 34.89 103.427817 0.00030825 35.48 35.90 61.8125287 0.00018423 13.51 335527.231
1 33.46 33.42 246.895854 0.00036833 34.88 34.49 127.781246 0.00019063 12.55 670314.356
1 31.21 31.80 959.889198 0.00051546 32.80 31.62 829.930195 0.00044567 11.14 1862188.34
IV. 1 29.83 29.49 3388.58842 0.01129982 31.34 31.73 1250.71331 0.00417071 13.66 299879.85
1 32.46 32.66 454.609063 0.01230866 34.92 34.53 124.132905 0.00336093 16.55 36934.0747
1 30.85 29.95 2116.37297 0.00163277 31.99 31.95 903.811275 0.00069729 11.64 1296185.6
1 33.42 32.54 355.073055 0.00270485 36.39 35.22 61.3429717 0.00046729 14.80 131272.775
V. 6 34.34 34.77 115.500842 459.983767 39.59 40.00 3.160815 12.5879913 32.97 0.25109765
6 35.13 35.93 60.4717648 3.44740929 40.00 38.71 4.77705791 0.27233328 27.11 17.54122
8 40.00 40.00 2.651597 0.00011009 40.00 40.00 2.6949909 0.00011189 17.14 24085.0003
8 35.75 36.59 39.0045578 8.6682E-05 37.20 38.65 13.8181213 3.0709E-05 13.10 449973.012
8 40.00 36.05 21.6521044 6.1562E-05 40.00 38.90 4.33619854 1.2329E-05 13.44 351709.506
10 40.00 40.00 2.651597 0.00181844 40.00 40.00 2.6949909 0.0018482 21.01 1458.16955
10 32.74 31.92 553.148976 0.00010017 34.71 35.70 92.4557174 1.6743E-05 9.64 5521954.71
10 40.00 40.00 2.651597 6.6533E-07 40.00 39.27 3.63370447 9.1175E-07 10.09 3985401.4
13 36.18 40.0 19.9055259 0.14283518 40.0 40.0 2.6949909 0.01933832 24.25 139.360108
13 40.0 38.63 4.74306628 0.01416179 39.16 37.94 8.46551086 0.02527622 23.04 334.91993
13 35.38 37.08 42.271478 0.01171786 40.0 40.0 2.6949909 0.00074706 19.76 3607.4395
15 29.38 28.62 5494.56256 0.00075007 31.82 31.75 1033.60621 0.0001411 9.25 7325391.53
15 40.0 40.0 2.651597 0.0428398 40.00 40.0 2.6949909 0.04354088 25.37 61.8956474
15 40.0 36.03 21.9350111 0.01910667 40.00 40.0 2.6949909 0.00234749 21.34 1148.02883
19 36.15 36.47 34.1743294 0.04307753 40.00 40.00 2.6949909 0.0033971 21.85 793.321551
VTicks
(part II)
p40 p24 18s rRNA
Experiment Day 1. Result 2. Result average
normaluzed
average
calibrated
1. Result 2. Result average
normaluzed
average
calibrated
Result calibrated
19 35.02 40.00 42.7457839 2.6343E-05 40.00 40.00 2.6949909 1.6608E-06 11.33 1622662.38
19 31.89 32.70 566.155122 0.00012651 35.39 36.34 57.0476635 1.2747E-05 9.93 4475340.89
20 33.30 33.54 251.169605 0.00012011 37.39 35.75 38.1736225 1.8255E-05 10.98 2091113.74
20 40.00 36.17 20.0343778 1.7867E-05 40.00 40.00 2.6949909 2.4034E-06 11.84 1121307.24
20 40.00 40.00 2.651597 1.9165E-06 40.00 40.00 2.6949909 1.9479E-06 11.55 1383538.81
23 36.19 34.96 61.625413 0.00597348 37.60 38.73 11.042197 0.00107034 18.31 10316.5064
23 31.40 31.60 945.788406 0.00150605 33.93 35.11 155.788389 0.00024807 12.64 627992.369
23 37.04 36.12 29.6208287 0.00033858 40.00 39.72 2.99789349 3.4267E-05 15.36 87485.3803
23 36.62 36.90 25.0042447 0.00178773 40.00 38.51 5.31155081 0.00037976 17.89 13986.5962
27 40.00 40.00 2.651597 0.0001855 40.00 40.00 2.6949909 0.00018854 17.86 14293.9883
27 40.00 40.00 2.651597 0.00014395 40.00 40.00 2.6949909 0.0001463 17.51 18420.5635
27 40.00 40.00 2.651597 0.00058291 40.00 40.00 2.6949909 0.00059245 19.44 4548.90807
35 40.00 40.00 2.651597 840.485713 40.00 40.00 2.6949909 854.240425 39.01 0.00315484
35 40.00 40.00 2.651597 0.06961535 40.00 40.00 2.6949909 0.07075462 26.04 38.0892585
35 40.00 40.00 2.651597 0.00013389 40.00 40.00 2.6949909 0.00013608 17.41 19804.9702
VI. 1 38.36 38.33 27.0002626 0.40572951 40.00 40.00 2.6949909 0.04049729 25.27 66.547446
1 35.30 36.16 133.995295 0.03032291 40.00 40.00 2.6949909 0.00060987 19.48 4418.94551
1 34.18 36.98 131.243428 0.00817655 38.71 38.43 7.63005395 0.00047536 17.70 16051.1988
10 36.10 36.54 96.7876057 0.0032806 37.93 39.81 7.57953027 0.00025691 16.86 29503.0046
10 36.58 40.00 21.4547938 0.00173506 37.68 37.89 13.4412639 0.001087 18.06 12365.4765
10 40.00 40.00 8.6883368 0.00813683 40.00 40.00 2.6949909 0.00252392 21.44 1067.77933
10 35.01 35.23 229.487864 0.00980848 38.87 40.00 4.40183926 0.00018814 17.18 23396.8905
20 32.82 34.02 616.505591 0.0231276 36.68 37.57 22.7473071 0.00085334 17.00 26656.7041
20 38.22 35.98 117.382028 0.00610121 39.38 38.76 5.41876 0.00028165 17.45 19239.1411
20 38.01 37.15 56.2326933 0.00201976 40.00 40.00 2.6949909 9.6798E-05 16.94 27841.2815
20 40.00 40.00 8.6883368 0.01619692 40.00 40.00 2.6949909 0.00502404 22.39 536.419216
20 35.90 34.67 297.202478 0.02334818 40.00 40.00 2.6949909 0.00021172 18.02 12729.149
20 36.44 34.81 265.27328 0.03886397 39.94 40.00 2.75483083 0.0004036 18.88 6825.68656
24 35.40 37.34 76.6693461 0.00332474 38.01 40.00 7.04116419 0.00030534 17.20 23060.2434
24 34.42 34.39 394.872599 0.00722911 40.00 40.00 2.6949909 4.9338E-05 16.01 54622.5723
24 32.55 32.19 1707.83569 0.00043794 36.62 36.67 30.6050184 7.8481E-06 10.12 3899695.38
24 35.30 34.37 370.842394 7.0142E-05 39.63 39.76 3.36482341 6.3643E-07 9.70 5287009.26
24 35.06 34.23 410.579237 0.00088638 38.31 36.48 21.8237355 4.7114E-05 13.06 463206.858
24 37.33 34.76 266.766135 0.02989101 39.53 40.00 3.24134137 0.00036319 18.51 8924.62726
29 33.90 34.01 519.768453 0.00513963 38.90 37.99 8.7654361 8.6675E-05 15.16 101129.544
29 36.16 35.70 155.313195 1.28828647 40.00 40.00 2.6949909 0.02235432 24.45 120.557965
29 33.90 33.85 569.110352 0.00170232 37.18 38.81 13.5755754 4.0607E-05 13.51 334313.727
29 40.00 40.00 8.6883368 0.93718243 40.00 40.00 2.6949909 0.29069984 27.99 9.27069962
29 36.36 37.17 66.7060418 0.04743433 40.00 40.00 2.6949909 0.00191639 21.06 1406.28189
29 40.00 40.00 8.6883368 0.0008361 40.00 40.00 2.6949909 0.00025934 18.30 10391.5368
VI
Ticks
(part III)
p40 p24 18s rRNA
Experiment Day 1. Result 2. Result average
normaluzed
average
calibrated
1. Result 2. Result average
normaluzed
average
calibrated
Result calibrated
30 28.59 28.00 28975.824 11.2915033 30.55 40.00 1264.91738 0.49292192 20.23 2566.16176
30 28.06 28.01 30362.9525 0.04152407 30.93 31.62 1541.80272 0.00210855 12.43 731213.262
30 33.30 32.93 1031.1282 0.00331612 37.37 36.14 31.1060371 0.00010004 13.61 310944.534
30 33.19 33.44 779.861432 0.13111927 35.43 40.00 38.2295424 0.00642759 19.07 5947.72534
30 40.00 40.00 8.6883368 1.0736E-05 40.00 39.22 3.71800213 4.5942E-06 12.29 809289.406
30 31.83 31.78 2329.98828 0.00435147 35.54 36.56 50.3294063 9.3995E-05 12.86 535448.301
35 40.00 38.36 23.7463583 42.9257008 40.00 40.00 2.6949909 4.87166796 31.88 0.55319675
35 40.00 40.00 8.6883368 324.755587 40.00 40.00 2.6949909 100.73428 36.06 0.02675346
35 40.00 40.00 8.6883368 4.85536909 40.00 40.00 2.6949909 1.50606219 30.26 1.7894287
35 40.00 40.00 8.6883368 31.950348 40.00 40.00 2.6949909 9.91051558 32.86 0.27193246
35 40.00 40.00 8.6883368 3183.47929 40.00 40.00 2.6949909 987.467213 39.21 0.0027292
35 40.00 40.00 8.6883368 4.54881312 40.00 40.00 2.6949909 1.41097315 30.17 1.9100228
35 40.00 40.00 8.6883368 24.7928301 40.00 40.00 2.6949909 7.69036159 32.51 0.35043748
Table C. (Part I-III) TaqMan® results of BDV infected ticks (Ixodes ricinus). Six independent experiments.
